Plurihormonal pituitary macroadenoma: a case report.
Nonfunctioning
Plurihormonal pituitary adenoma
Silent corticotroph
Silent gonadotroph
Silent pituitary adenomas
Silent somatotroph adenomas
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
29 Jul 2021
29 Jul 2021
Historique:
received:
19
10
2019
accepted:
07
06
2021
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
31
7
2021
Statut:
epublish
Résumé
Plurihormonal pituitary adenomas are a unique type of pituitary adenomas that secrete two or more pituitary hormones normally associated with separate cell types that have different immunocytochemical and ultrastructural features. Although they represent 10-15% of all pituitary tumors, only a small fraction of plurihormonal pituitary adenomas clinically secrete multiple hormones. The most common hormone combinations secreted by plurihormonal pituitary adenomas are growth hormone, prolactin, and one or more glycoprotein hormones. The most common hormonal symptom is acromegaly (50%). The aim of this case report is to bring awareness about this rare type of pituitary adenomas and to describe the unique presentation of our patient, even though plurihormonal pituitary adenomas are known mostly as a clinically silent tumors. Herein, we describe an unusual case of plurihormonal pituitary adenoma with triple-positive staining for adrenocorticotropic hormone, growth hormone, and prolactin. The patient is a 65-year-old Egyptian woman who presented with mass effect symptoms of the pituitary tumor, which primarily manifested as severe headache and visual field defects. She also presented with some cushingoid features, and further analysis confirmed Cushing's disease; slightly high prolactin and normal growth hormone levels were observed. She underwent transsphenoidal surgery and has been in remission thus far. Only a few cases have been reported in the literature, but none has exhibited silent acromegaly or mass effect symptoms as the initial presentation. This case highlights an unusual plurihormonal pituitary adenoma case with a rare combination of secreted hormones; mass effect symptoms were dominant, as were uncommon visual field defects. Our case further proves that immunohistochemical analyses of all pituitary hormones are needed to ensure correct diagnosis and to alert clinicians to the need for more rigorous follow-up due to the higher morbidity of these patients. Our case report approval number Federal Wide Assurance NIH, USA is FWA00018774 IRB registration number with OHRP/NIH is IRB00010471.
Sections du résumé
BACKGROUND
BACKGROUND
Plurihormonal pituitary adenomas are a unique type of pituitary adenomas that secrete two or more pituitary hormones normally associated with separate cell types that have different immunocytochemical and ultrastructural features. Although they represent 10-15% of all pituitary tumors, only a small fraction of plurihormonal pituitary adenomas clinically secrete multiple hormones. The most common hormone combinations secreted by plurihormonal pituitary adenomas are growth hormone, prolactin, and one or more glycoprotein hormones. The most common hormonal symptom is acromegaly (50%). The aim of this case report is to bring awareness about this rare type of pituitary adenomas and to describe the unique presentation of our patient, even though plurihormonal pituitary adenomas are known mostly as a clinically silent tumors.
CASE PRESENTATION
METHODS
Herein, we describe an unusual case of plurihormonal pituitary adenoma with triple-positive staining for adrenocorticotropic hormone, growth hormone, and prolactin. The patient is a 65-year-old Egyptian woman who presented with mass effect symptoms of the pituitary tumor, which primarily manifested as severe headache and visual field defects. She also presented with some cushingoid features, and further analysis confirmed Cushing's disease; slightly high prolactin and normal growth hormone levels were observed. She underwent transsphenoidal surgery and has been in remission thus far. Only a few cases have been reported in the literature, but none has exhibited silent acromegaly or mass effect symptoms as the initial presentation.
CONCLUSION
CONCLUSIONS
This case highlights an unusual plurihormonal pituitary adenoma case with a rare combination of secreted hormones; mass effect symptoms were dominant, as were uncommon visual field defects. Our case further proves that immunohistochemical analyses of all pituitary hormones are needed to ensure correct diagnosis and to alert clinicians to the need for more rigorous follow-up due to the higher morbidity of these patients. Our case report approval number Federal Wide Assurance NIH, USA is FWA00018774 IRB registration number with OHRP/NIH is IRB00010471.
Identifiants
pubmed: 34321093
doi: 10.1186/s13256-021-02948-6
pii: 10.1186/s13256-021-02948-6
pmc: PMC8320198
doi:
Substances chimiques
Adrenocorticotropic Hormone
9002-60-2
Prolactin
9002-62-4
Growth Hormone
9002-72-6
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
407Informations de copyright
© 2021. The Author(s).
Références
Eur J Endocrinol. 2007 Feb;156(2):203-16
pubmed: 17287410
Trends Endocrinol Metab. 1989 Nov-Dec;1(2):104-7
pubmed: 18411100
Clin Endocrinol (Oxf). 2003 Jan;58(1):59-64
pubmed: 12519413
Brain Tumor Pathol. 2018 Apr;35(2):51-56
pubmed: 29687298
BMC Endocr Disord. 2017 Sep 2;17(1):54
pubmed: 28865461
Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):447-60
pubmed: 22863387
Acta Neurochir (Wien). 1996;138(8):1002-7
pubmed: 8890999
World Neurosurg. 2018 Jun;114:e158-e164
pubmed: 29501516
Endocr Pract. 2012 Sep-Oct;18(5):e121-6
pubmed: 22441009
J Clin Endocrinol Metab. 2014 Jun;99(6):2069-76
pubmed: 24552222
Endokrynol Pol. 2010 Jan-Feb;61(1):63-6
pubmed: 20205106
Nat Rev Endocrinol. 2011 May;7(5):257-66
pubmed: 21423242
Mod Pathol. 2002 Oct;15(10):1102-5
pubmed: 12379758
Endocr J. 2006 Oct;53(5):679-85
pubmed: 16926523
J Neurosurg. 2009 Feb;110(2):369-73
pubmed: 18991502
Histochem Cell Biol. 2008 Sep;130(3):495-507
pubmed: 18688636
Endocr Pathol. 2017 Sep;28(3):228-243
pubmed: 28766057
Histopathology. 2001 Sep;39(3):310-9
pubmed: 11532042
Case Rep Endocrinol. 2012;2012:529730
pubmed: 23320206
Am J Med Sci. 2002 Dec;324(6):326-30
pubmed: 12495300